Correction to Eli Lilly's Omvoh Hits Goal in Phase 3 Study Article on Oct. 19
Dow Jones10-20 22:08
Eli Lilly said 81% of patients achieved clinical response to Omvoh induction at week 12 in the Phase 3 study in children ages 4 to 17 with moderately to severely active ulcerative colitis, including clinical, symptomatic and endoscopic outcomes. Among responders ages 6 to 17, 50% achieved clinical remission at 52 weeks." "Eli Lilly's Omvoh Hits Goal in Phase 3 Study in Children With Ulcerative Colitis," at 6:35 a.m. ET on Oct. 19, incorrectly said the study involved children ages 6 to 17.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments